>
Switch to:

ITeos Therapeutics ROC (Joel Greenblatt) %

: -2,241.44% (As of Jun. 2021)
View and export this data going back to 2020. Start your Free Trial

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. ITeos Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2021 was -2,241.44%.

The historical rank and industry rank for ITeos Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

NAS:ITOS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2924.63   Med: -1867.5   Max: -1555.36
Current: -2465.97

-2924.63
-1555.36

During the past 3 years, ITeos Therapeutics's highest ROC (Joel Greenblatt) % was -1555.36%. The lowest was -2924.63%. And the median was -1867.50%.

NAS:ITOS's ROC (Joel Greenblatt) % is ranked lower than
99.99% of the 318 Companies
in the Biotechnology industry.

( Industry Median: -691.89 vs. NAS:ITOS: -2465.97 )

ITeos Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


ITeos Therapeutics ROC (Joel Greenblatt) % Historical Data

The historical data trend for ITeos Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ITeos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20
ROC (Joel Greenblatt) %
-1,555.36 -1,867.50 -2,924.63

ITeos Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
ROC (Joel Greenblatt) % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,329.14 -3,452.48 -4,431.98 -1,917.05 -2,241.44

Competitive Comparison

For the Biotechnology subindustry, ITeos Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

ITeos Therapeutics ROC (Joel Greenblatt) % Distribution

For the Biotechnology industry and Healthcare sector, ITeos Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where ITeos Therapeutics's ROC (Joel Greenblatt) % falls into.



ITeos Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Mar. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.293) - (10.614 + 0.666 + -1.7763568394003E-15)
=-8.987

Working Capital(Q: Jun. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.603) - (19.231 + 0.977 + 0)
=-17.605

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of ITeos Therapeutics for the quarter that ended in Jun. 2021 can be restated as:

ROC (Joel Greenblatt) %(Q: Jun. 2021 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2021  Q: Jun. 2021
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-106.076/( ( (4.396 + max(-8.987, 0)) + (5.069 + max(-17.605, 0)) )/ 2 )
=-106.076/( ( 4.396 + 5.069 )/ 2 )
=-106.076/4.7325
=-2,241.44 %

Note: The EBIT data used here is four times the quarterly (Jun. 2021) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ITeos Therapeutics  (NAS:ITOS) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


ITeos Therapeutics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of ITeos Therapeutics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


ITeos Therapeutics Business Description

ITeos Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 541714 SIC : 2833
Comparable Companies
Traded in Other Exchanges
N/A
Address
139 Main Street, Cambridge, MA, USA, 02142
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
Executives
Evnin Luke 10 percent owner THE JOHN HANCOCK TOWER 200 CLARENDON STREET, 54TH STREET BOSTON MA 02116
Mpm Bioventures 2018 Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2018 Gp Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Asset Management Investors Bv2018 Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2018, L.p. 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2018 (b), L.p. 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2014 Gp Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2014 Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Asset Management Investors Bv2014 Llc 10 percent owner C/O MPM ASSET MANAGEMENT LLC 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2014 (b), L.p. 10 percent owner C/O MPM ASSET MANAGEMENT LLC 450 KENDALL STREET CAMBRIDGE MA 02124
Mpm Bioventures 2014, L.p. 10 percent owner C/O MPM ASSET MANAGEMENT LLC 450 KENDALL STREET CAMBRIDGE MA 02142
Oncology Impact Fund (cayman) Management L.p. other: X* 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Oncology Impact Management Gp Llc other: X* 450 KENDALL STREET CAMBRIDGE MA 02142
Ubs Oncology Impact Fund L.p. other: X* 450 KENDALL STREET CAMBRIDGE MA 02142
Davis Aaron I. director, 10 percent owner 11682 EL CAMINO REAL, SUITE 320 SAN DIEGO CA 92130

ITeos Therapeutics Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)